SPRY ARS Corp: Enterprise Value to EBITDA Ratio
Rising demand for needle-free allergy sprays is driving the expansion of ARS Pharmaceuticals (SPRY), as confirmed by the precise GURU.Markets chart. The EV/EBITDA multiple reflects the asset's dynamics, with the indicator currently standing at 0.00. Business efficiency is bolstered by packaging robotization and AI-driven document management, while its status as an innovator in nasal therapy formulations strengthens patient trust.
Comprehensive metric breakdowns and analytics for ars-pharma.com (SPRY)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity ARS Pharmaceuticals|SPRY - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital ARS Pharmaceuticals, Inc.|SPRY - Company Aggregate Debts|Debt to Book Capitalization Ratio ARS Corp|SPRY - Company Long-Term Loans and Borrowings|Company Short-Term Debt ARS Pharmaceuticals|Quick Liquidity Indicator ars-pharma.com
- financial results and valuation multiples details:
SPRY - Final Profit|Expected Profit ARS Pharmaceuticals|SPRY - Market Cap to Net Income|Forward P/E Multiple ARS Pharmaceuticals|SPRY - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple ARS Corp|SPRY - Operating profit EBITDA|Earnings per share for the last twelve months ARS Pharmaceuticals|SPRY - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months ars-pharma.com|SPRY - Net earnings per share growth this year|Earnings growth forecast for next year ARS Pharmaceuticals
Fundamental company analysis:SPRY (ARS Pharma)
This indicator compares the total enterprise value, including net debt, with its operating profit before taxes and depreciation, determining the real price per unit of generated cash flow. The EV/EBITDA ratio trend on the valuation chart reflects market expectations for the capitalization of ARS Pharmaceuticals (SPRY), where the exceptional patent moat of the needle-free spray may justify a high asset valuation relative to current operating income.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals, Inc.)|EV/EBITDA Multiple MannKind Corp MNKD|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation PCRX (Pacira Corp)|Theravance Biopharma (TBPH) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AQST - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio SCPH|TECX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tonix Pharmaceuticals Inc. (TNXP)|SXTC: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|Business Value to Operating Income Before Depreciation BHST|eXoZymes - EV/EBITDA Multiple|ORMP - EV/EBITDA Multiple|enterabio.com (ENTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MindWalk Therapeutics - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ABVC BioPharma|Enterprise Value to EBITDA Ratio cumberlandpharma.com (CPIX)|EV/EBITDA Multiple QNTM|EV/EBITDA Multiple FibroGen Inc (FGEN)|EV/EBITDA Multiple TELO (Telomir Pharma)|RANI - Enterprise Value to EBITDA Ratio|Synergy CHC Corporation - EV/EBITDA Multiple|Company Value to EBITDA Rallybio Corporation|LEXX (lexariabioscience.com) - Enterprise Value to EBITDA Ratio|Pulmatrix Inc (PULM) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PTHL|APM (Aptorum) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple LYRA|Total Company Value to Operating Income Before Depreciation Ratio impactbiomedinc.com|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals, Inc.)|YCBD - Enterprise Value to EBITDA Ratio|PainReform Limited - EV/EBITDA Multiple|CYTO - EV/EBITDA Multiple|Lipella Pharmaceuticals (LIPO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OPTN (optinose.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals, Inc.|Procaps Group (PROC) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|Total Company Value to Operating Income Before Depreciation Ratio Qilian International Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|TFFP (tffpharma.com) - Company Value to Operating Income Before Depreciation Ratio
